Yuta Kajiyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuta Kajiyama has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
- Hideki Mochizuki
Department of Neurology, Graduate School of Medicine, The University of Osaka, Suita, Japan
13 shared publications - Gajanan S. Revankar
Center for Global Health, Department of Medical Innovation, Osaka University Hospital
6 shared publications - Kensuke Ikenaka
Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan
5 shared publications - Kotaro Ogawa
Department of Neurology, Graduate School of Medicine, The University of Osaka, Suita, Japan
4 shared publications - Seira Taniguchi
Department of Rehabilitation Sciences, Neurorehabilitation Research Group (eNRGy) KU Leuven Leuven Belgium
4 shared publications - Yasuyoshi Kimura
Department of Neurology Osaka University Graduate School of Medicine Osaka Japan
4 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by Taylor & Francis in Dialogues in clinical neuroscience
- Vol. 28 (1) , 250-258
Poor sleep quality correlates with axial symptoms and mood problems in Parkinson’s disease
Sleep disturbances and impaired bed mobility are common in Parkinson’s disease (PD). We examined whether objectively measured sleep efficiency is associated with axial motor impairment and explored its potential relationship with cognitive and mood profiles. Twenty-eight patients with PD underwent single-night EEG-based sleep monitoring and assessment of nocturnal turning. Partial correlations between sleep metrics and scores on motor, cognitive and mood outcomes were analysed, controlling for age, sex and the MDS-UPDRS 3. Family-wise error (FWE) correction was applied within each sleep predictor. Poor sleep efficiency correlated with higher MDS-UPDRS axial subscore (rpartial = −.615) and this association survived stringent correction for multiple comparisons (FWE-p = .018). However, its associations with PIGD and clinically rated freezing of gait did not remain significant after the correction. Exploratory analyses showed the relationships of N1 percentage with mood disturbances and REM latency with self-reported freezing of gait, of which only the relationship of N1 percentage with depression score showed a trend towards significance after the correction (rpartial =.551, FWE-p = .074). Poor objective sleep quality was robustly associated with axial motor severity in PD, independent of overall motor burden. Sleep efficiency may represent a clinically accessible marker of shared brainstem-related pathology underlying axial dysfunction.
- 15 June 2026
- Published by Taylor & Francis in Dialogues in clinical neuroscience
- Vol. 28 (1) , 250-258
Open AccessPoor sleep quality correlates with axial symptoms and mood problems in Parkinson’s disease
Sleep disturbances and impaired bed mobility are common in Parkinson’s disease (PD). We examined whether objectively measured sleep efficiency is associated with axial motor impairment and explored its potential relationship with cognitive and mood profiles. Twenty-eight patients with PD underwent single-night EEG-based sleep monitoring and assessment of nocturnal turning. Partial correlations between sleep metrics and scores on motor, cognitive and mood outcomes were analysed, controlling for age, sex and the MDS-UPDRS 3. Family-wise error (FWE) correction was applied within each sleep predictor. Poor sleep efficiency correlated with higher MDS-UPDRS axial subscore (rpartial = −.615) and this association survived stringent correction for multiple comparisons (FWE-p = .018). However, its associations with PIGD and clinically rated freezing of gait did not remain significant after the correction. Exploratory analyses showed the relationships of N1 percentage with mood disturbances and REM latency with self-reported freezing of gait, of which only the relationship of N1 percentage with depression score showed a trend towards significance after the correction (rpartial =.551, FWE-p = .074). Poor objective sleep quality was robustly associated with axial motor severity in PD, independent of overall motor burden. Sleep efficiency may represent a clinically accessible marker of shared brainstem-related pathology underlying axial dysfunction.
- Open Access
- 1 October 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (5)
Atypical Psychosis in Parkinson Disease
Atypical psychosis, characterized by severe delusions, paranoia, and auditory or somatic hallucinations, is a notable complication of continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa therapy in Parkinson disease (PD). The aim of this study was to identify clinical predictors of CSCI-induced psychosis to understand its potential mechanisms and evaluate predictive measures for early detection and management. This retrospective cohort study included patients with PD treated with CSCI (n = 23) and an independent PD database cohort (n = 94) from Osaka University Hospital. In the CSCI cohort, clinical data such as psychosis information and answers from Parkinson's Disease Questionnaire (PDQ39) and the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease–Current Symptoms (QUIP-CS) were collected. Statistical analyses included independent t tests and linear regression to identify predictors of atypical psychosis within a year of CSCI initiation. In the PD database cohort, potential relationships between QUIP-CS scores and other clinical parameters were explored using correlational analyses. Among the 23 patients, 6 developed atypical psychosis, all occurring within 6 months, with 4 of them discontinuing CSCI. Patients who developed atypical psychosis had significantly higher QUIP-CS scores before CSCI (adjusted p = 0.0032). Linear regression identified QUIP-CS as the sole predictor of atypical psychosis onset (coefficient = 0.199, p < 0.001). Among the PDQ39 subitems, item 27 showed a significant correlation with QUIP-CS scores (r = 0.722, adjusted p = 0.0128). Furthermore, a composite score comprising PDQ39 items 20, 27, 29, 31, and 36 (PDQ39_sub5) showed an even stronger correlation with QUIP-CS scores (r = 0.770, p = 0.0000704). This association was independently confirmed in the PD database cohort (r = 0.415, p = 0.00003). Finally, PDQ39_sub5 effectively stratified survival curves for psychosis onset in the CSCI cohort (p = 0.008). CSCI-induced psychosis is distinct from visual hallucinations observed in typical PD psychosis and likely involves mechanisms in mesolimbic circuits and impulsive-compulsive behaviors associated with dopamine dysregulation. While QUIP-CS is rarely used in clinical practice, widely used PDQ39_sub5 offers a practical way to identify individual psychosis risk. These findings potentially offer tailored strategies to predict and manage atypical psychosis in patients with PD receiving advanced dopaminergic therapies.
- 1 October 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (5)
Open AccessAtypical Psychosis in Parkinson Disease
Atypical psychosis, characterized by severe delusions, paranoia, and auditory or somatic hallucinations, is a notable complication of continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa therapy in Parkinson disease (PD). The aim of this study was to identify clinical predictors of CSCI-induced psychosis to understand its potential mechanisms and evaluate predictive measures for early detection and management. This retrospective cohort study included patients with PD treated with CSCI (n = 23) and an independent PD database cohort (n = 94) from Osaka University Hospital. In the CSCI cohort, clinical data such as psychosis information and answers from Parkinson's Disease Questionnaire (PDQ39) and the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease–Current Symptoms (QUIP-CS) were collected. Statistical analyses included independent t tests and linear regression to identify predictors of atypical psychosis within a year of CSCI initiation. In the PD database cohort, potential relationships between QUIP-CS scores and other clinical parameters were explored using correlational analyses. Among the 23 patients, 6 developed atypical psychosis, all occurring within 6 months, with 4 of them discontinuing CSCI. Patients who developed atypical psychosis had significantly higher QUIP-CS scores before CSCI (adjusted p = 0.0032). Linear regression identified QUIP-CS as the sole predictor of atypical psychosis onset (coefficient = 0.199, p < 0.001). Among the PDQ39 subitems, item 27 showed a significant correlation with QUIP-CS scores (r = 0.722, adjusted p = 0.0128). Furthermore, a composite score comprising PDQ39 items 20, 27, 29, 31, and 36 (PDQ39_sub5) showed an even stronger correlation with QUIP-CS scores (r = 0.770, p = 0.0000704). This association was independently confirmed in the PD database cohort (r = 0.415, p = 0.00003). Finally, PDQ39_sub5 effectively stratified survival curves for psychosis onset in the CSCI cohort (p = 0.008). CSCI-induced psychosis is distinct from visual hallucinations observed in typical PD psychosis and likely involves mechanisms in mesolimbic circuits and impulsive-compulsive behaviors associated with dopamine dysregulation. While QUIP-CS is rarely used in clinical practice, widely used PDQ39_sub5 offers a practical way to identify individual psychosis risk. These findings potentially offer tailored strategies to predict and manage atypical psychosis in patients with PD receiving advanced dopaminergic therapies.
- 9 January 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (4) , 547-550
Focused Ultrasound Lesioning of the Subthalamic Nucleus for Asymmetric Parkinson's Disease in Japan
- 9 January 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (4) , 547-550
Focused Ultrasound Lesioning of the Subthalamic Nucleus for Asymmetric Parkinson's Disease in Japan
- Open Access
- 18 September 2024
- Published by Wiley in Movement Disorders
- Vol. 39 (11) , 1982-1992
New Insights into Freezing of Gait in Parkinson's Disease from Spectral Dynamic Causal Modeling
Background: Freezing of gait is one of the most disturbing motor symptoms of Parkinson's disease (PD). However, the effective connectivity between key brain hubs that are associated with the pathophysiological mechanism of freezing of gait remains elusive.Objective: The aim of this study was to identify effective connectivity underlying freezing of gait.Methods: This study applied spectral dynamic causal modeling (DCM) of resting‐state functional magnetic resonance imaging in dedicated regions of interest determined using a data‐driven approach.Results: Abnormally increased functional connectivity between the bilateral dorsolateral prefrontal cortex (DLPFC) and the bilateral mesencephalic locomotor region (MLR) was identified in freezers compared with nonfreezers. Subsequently, spectral DCM analysis revealed that increased top‐down excitatory effective connectivity from the left DLPFC to bilateral MLR and an independent self‐inhibitory connectivity within the left DLPFC in freezers versus nonfreezers (>99% posterior probability) were inversely associated with the severity of freezing of gait. The lateralization of these effective connectivity patterns was not attributable to the initial dopaminergic deficit nor to structural changes in these regions.Conclusions: We have identified novel effective connectivity and an independent self‐inhibitory connectivity underlying freezing of gait. Our findings imply that modulating the effective connectivity between the left DLPFC and MLR through neurostimulation or other interventions could be a target for reducing freezing of gait in PD. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 18 September 2024
- Published by Wiley in Movement Disorders
- Vol. 39 (11) , 1982-1992
Open AccessNew Insights into Freezing of Gait in Parkinson's Disease from Spectral Dynamic Causal Modeling
Background: Freezing of gait is one of the most disturbing motor symptoms of Parkinson's disease (PD). However, the effective connectivity between key brain hubs that are associated with the pathophysiological mechanism of freezing of gait remains elusive.Objective: The aim of this study was to identify effective connectivity underlying freezing of gait.Methods: This study applied spectral dynamic causal modeling (DCM) of resting‐state functional magnetic resonance imaging in dedicated regions of interest determined using a data‐driven approach.Results: Abnormally increased functional connectivity between the bilateral dorsolateral prefrontal cortex (DLPFC) and the bilateral mesencephalic locomotor region (MLR) was identified in freezers compared with nonfreezers. Subsequently, spectral DCM analysis revealed that increased top‐down excitatory effective connectivity from the left DLPFC to bilateral MLR and an independent self‐inhibitory connectivity within the left DLPFC in freezers versus nonfreezers (>99% posterior probability) were inversely associated with the severity of freezing of gait. The lateralization of these effective connectivity patterns was not attributable to the initial dopaminergic deficit nor to structural changes in these regions.Conclusions: We have identified novel effective connectivity and an independent self‐inhibitory connectivity underlying freezing of gait. Our findings imply that modulating the effective connectivity between the left DLPFC and MLR through neurostimulation or other interventions could be a target for reducing freezing of gait in PD. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 29 January 2024
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 12 (1) , e1174
Decreased hepatic enzymes reflect the decreased vitamin B6 levels in Parkinson's disease patients
The study aims to investigate the vitamin B6 levels in Parkinson's disease (PD) patients and their association with liver enzymes and evaluate how much dysregulation is associated with levodopa dose. Furthermore, to evaluate the effect of Opicapone, a catechol‐o‐methyl‐transferase inhibitor, on vitamin B6 levels by monitoring the AST and ALT levels in patients treated with Levodopa–Carbidopa Intestinal Gel Infusion (LCIG). For these aims, serum vitamin B6 levels were measured (PD, n = 72 and controls, n = 31). The vitamin B6 level was compared with the total levodopa dose, clinical parameters, and blood homocysteine, albumin, and hemoglobin levels in PD patients. Correlations between vitamin B6 levels and AST and ALT levels, as well as the ratio ALT/AST, were analyzed. Changes in the AST and ALT levels and ALT/AST were analyzed in the patients treated with LCIG before and after the therapy (n = 24) and in the patients treated with LCIG + Opicapone before and after Opicapone treatment (n = 12). We found vitamin B6 levels were significantly lower in PD patients. Total levodopa dose and albumin levels were independently associated with vitamin B6 levels. Decreased vitamin B6 levels appeared as lower AST and ALT levels and ALT/AS. Treatment with LCIG decreased the AST and ALT levels and ALT/AST. Adjunctive therapy with Opicapone to LCIG ameliorated the decreased ALT and ALT/AST. We conclude that the ALT and ALT/AST can be useful parameters for monitoring vitamin B6 levels and Opicapone can ameliorate the dysregulated vitamin B6 in PD patients.
- 29 January 2024
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 12 (1) , e1174
Open AccessDecreased hepatic enzymes reflect the decreased vitamin B6 levels in Parkinson's disease patients
The study aims to investigate the vitamin B6 levels in Parkinson's disease (PD) patients and their association with liver enzymes and evaluate how much dysregulation is associated with levodopa dose. Furthermore, to evaluate the effect of Opicapone, a catechol‐o‐methyl‐transferase inhibitor, on vitamin B6 levels by monitoring the AST and ALT levels in patients treated with Levodopa–Carbidopa Intestinal Gel Infusion (LCIG). For these aims, serum vitamin B6 levels were measured (PD, n = 72 and controls, n = 31). The vitamin B6 level was compared with the total levodopa dose, clinical parameters, and blood homocysteine, albumin, and hemoglobin levels in PD patients. Correlations between vitamin B6 levels and AST and ALT levels, as well as the ratio ALT/AST, were analyzed. Changes in the AST and ALT levels and ALT/AST were analyzed in the patients treated with LCIG before and after the therapy (n = 24) and in the patients treated with LCIG + Opicapone before and after Opicapone treatment (n = 12). We found vitamin B6 levels were significantly lower in PD patients. Total levodopa dose and albumin levels were independently associated with vitamin B6 levels. Decreased vitamin B6 levels appeared as lower AST and ALT levels and ALT/AS. Treatment with LCIG decreased the AST and ALT levels and ALT/AST. Adjunctive therapy with Opicapone to LCIG ameliorated the decreased ALT and ALT/AST. We conclude that the ALT and ALT/AST can be useful parameters for monitoring vitamin B6 levels and Opicapone can ameliorate the dysregulated vitamin B6 in PD patients.
- 18 August 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (12) , 1172-1176
Adult-onset botulism in a Japanese woman with prolonged spore excretion
- 18 August 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (12) , 1172-1176
Adult-onset botulism in a Japanese woman with prolonged spore excretion
- Open Access
- 30 December 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (12) , e0279747
Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson’s disease: A retrospective study
Patients with Parkinson’s disease (PD) often suffer from sleep disturbances, including excessive daytime sleepiness (EDS) and rapid eye movement sleep behavior disorder (RBD). These symptoms are also experienced by patients with narcolepsy, which is characterized by orexin neuronal loss. In PD, a decrease in orexin neurons is observed pathologically, but the association between sleep disturbance in PD and cerebrospinal fluid (CSF) orexin levels is still unclear. This study aimed to clarify the role of orexin as a biomarker in patients with PD. CSF samples were obtained from a previous cohort study conducted between 2015 and 2020. We cross-sectionally and longitudinally examined the association between CSF orexin levels, sleep, and clinical characteristics. We analyzed 78 CSF samples from 58 patients with PD and 21 samples from controls. CSF orexin levels in patients with PD (median = 272.0 [interquartile range = 221.7–334.5] pg/mL) were lower than those in controls (352.2 [296.2–399.5] pg/mL, p = 0.007). There were no significant differences in CSF orexin levels according to EDS, RBD, or the use of dopamine agonists. Moreover, no significant correlation was observed between CSF orexin levels and clinical characteristics by multiple linear regression analysis. Furthermore, the longitudinal changes in orexin levels were also not correlated with clinical characteristics. This study showed decreased CSF orexin levels in patients with PD, but these levels did not show any correlation with any clinical characteristics. Our results suggest the limited efficacy of CSF orexin levels as a biomarker for PD, and that sleep disturbances may also be affected by dysfunction of the nervous system other than orexin, or by dopaminergic treatments in PD. Understanding the reciprocal role of orexin among other neurotransmitters may provide a better treatment strategy for sleep disturbance in patients with PD.
- 30 December 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (12) , e0279747
Open AccessDecreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson’s disease: A retrospective study
Patients with Parkinson’s disease (PD) often suffer from sleep disturbances, including excessive daytime sleepiness (EDS) and rapid eye movement sleep behavior disorder (RBD). These symptoms are also experienced by patients with narcolepsy, which is characterized by orexin neuronal loss. In PD, a decrease in orexin neurons is observed pathologically, but the association between sleep disturbance in PD and cerebrospinal fluid (CSF) orexin levels is still unclear. This study aimed to clarify the role of orexin as a biomarker in patients with PD. CSF samples were obtained from a previous cohort study conducted between 2015 and 2020. We cross-sectionally and longitudinally examined the association between CSF orexin levels, sleep, and clinical characteristics. We analyzed 78 CSF samples from 58 patients with PD and 21 samples from controls. CSF orexin levels in patients with PD (median = 272.0 [interquartile range = 221.7–334.5] pg/mL) were lower than those in controls (352.2 [296.2–399.5] pg/mL, p = 0.007). There were no significant differences in CSF orexin levels according to EDS, RBD, or the use of dopamine agonists. Moreover, no significant correlation was observed between CSF orexin levels and clinical characteristics by multiple linear regression analysis. Furthermore, the longitudinal changes in orexin levels were also not correlated with clinical characteristics. This study showed decreased CSF orexin levels in patients with PD, but these levels did not show any correlation with any clinical characteristics. Our results suggest the limited efficacy of CSF orexin levels as a biomarker for PD, and that sleep disturbances may also be affected by dysfunction of the nervous system other than orexin, or by dopaminergic treatments in PD. Understanding the reciprocal role of orexin among other neurotransmitters may provide a better treatment strategy for sleep disturbance in patients with PD.
- Open Access
- 28 December 2022
- Published by Elsevier in NeuroImage: Clinical
- Vol. 37, 103307
Neural correlates of impulsive compulsive behaviors in Parkinson’s disease: A Japanese retrospective study
- 28 December 2022
- Published by Elsevier in NeuroImage: Clinical
- Vol. 37, 103307
Open AccessNeural correlates of impulsive compulsive behaviors in Parkinson’s disease: A Japanese retrospective study
- Open Access
- 22 October 2022
- Published by Hindawi Limited in Case Reports in Neurological Medicine
- Vol. 2022, 1-5
Guillain–Barré Syndrome Associated with COVID-19 in a Japanese Male
April 2021 saw a widespread outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Osaka, Japan. We encountered the case of a 52-year-old man who had GuillainBarré syndrome associated with coronavirus disease 2019 (COVID-19). After the relief of the respiratory symptoms owing to COVID-19, the patient experienced muscle weakness, which spread from his fingers to his extremities, and was unable to walk. Further examinations revealed mild protein elevation in the cerebrospinal fluid. In addition, nerve conduction studies showed demyelinating polyneuropathy, leading to the diagnosis of GuillainBarré syndrome. After the administration of intravenous immunoglobulin and intravenous methylprednisolone, his symptoms drastically improved, and he was able to walk unaided 21 days after the onset of symptoms. On day 40, the patient was discharged with minimal muscle fatigue. Because GuillainBarré syndrome associated with COVID-19 is expected to have a good prognosis, early diagnosis and treatment are important. Therefore, GuillainBarré syndrome should be considered as a possible factor for muscle weakness during and after COVID-19 treatment.
- 22 October 2022
- Published by Hindawi Limited in Case Reports in Neurological Medicine
- Vol. 2022, 1-5
Open AccessGuillain–Barré Syndrome Associated with COVID-19 in a Japanese Male
April 2021 saw a widespread outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Osaka, Japan. We encountered the case of a 52-year-old man who had GuillainBarré syndrome associated with coronavirus disease 2019 (COVID-19). After the relief of the respiratory symptoms owing to COVID-19, the patient experienced muscle weakness, which spread from his fingers to his extremities, and was unable to walk. Further examinations revealed mild protein elevation in the cerebrospinal fluid. In addition, nerve conduction studies showed demyelinating polyneuropathy, leading to the diagnosis of GuillainBarré syndrome. After the administration of intravenous immunoglobulin and intravenous methylprednisolone, his symptoms drastically improved, and he was able to walk unaided 21 days after the onset of symptoms. On day 40, the patient was discharged with minimal muscle fatigue. Because GuillainBarré syndrome associated with COVID-19 is expected to have a good prognosis, early diagnosis and treatment are important. Therefore, GuillainBarré syndrome should be considered as a possible factor for muscle weakness during and after COVID-19 treatment.
- Open Access
Neural Correlates of Impulsive Compulsive Behaviors in Parkinson’s Disease: A Japanese Retrospective Study
Background: Impulsive compulsive behavior (ICB) often disturb patients with Parkinson’s Disease (PD), of which impulse control disorder (ICD) and dopamine dysregulation syndrome (DDS) are two major subsets. Although the nucleus accumbens (NAcc) is involved in ICB, it remains unclear how the NAcc affects cortical function and defines the different behavioral characteristics of ICD and DDS. Objectives: To identify the most involved cortico-striatal network in ICB and the differences in these networks between patients with ICD and those with DDS using structural and resting-state functional magnetic resonance imaging. Methods: Patients with PD were recruited using the data from a previous cohort study and were divided into patients with ICB (ICB group) and those without ICB (non-ICB group) using the Japanese version of the Questionnaire for Impulsive Compulsive Disorders in Parkinson’s Disease (J-QUIP). From these two groups, we extracted 37 pairs matched for age, sex, disease duration, and levodopa equivalent daily dose of dopamine agonists. Patients with ICB were further classified as either having ICD or DDS based on the J-QUIP subscore. General linear models were used to compare the gray matter volume and functional connectivity (FC) of the NAcc, caudate, and putamen between the ICB and non-ICB groups and between patients with ICD and those with DDS. Results: We found no significant differences in gray matter volume between the ICB and non-ICB groups or between patients with ICD and those with DDS. Compared with the non-ICB group, the FC of the right NAcc in the ICB group was lower in the bilateral ventromedial prefrontal cortex and higher in the left middle occipital gyrus. Patients with DDS showed higher FC between the right putamen and left superior temporal gyrus and higher FC between the left caudate and bilateral middle occipital gyrus than patients with ICD. In contrast, patients with ICD exhibited higher FC between the left NAcc and the right posterior cingulate cortex than patients with DSS. Conclusions: The functionally altered network between the right NAcc and ventromedial prefrontal cortex was associated with the presence of ICB in PD, and the surrounding cortico-striatal networks may differentiate between the behavioral characteristics of patients with ICD and those with DDS.
Open AccessNeural Correlates of Impulsive Compulsive Behaviors in Parkinson’s Disease: A Japanese Retrospective Study
Background: Impulsive compulsive behavior (ICB) often disturb patients with Parkinson’s Disease (PD), of which impulse control disorder (ICD) and dopamine dysregulation syndrome (DDS) are two major subsets. Although the nucleus accumbens (NAcc) is involved in ICB, it remains unclear how the NAcc affects cortical function and defines the different behavioral characteristics of ICD and DDS. Objectives: To identify the most involved cortico-striatal network in ICB and the differences in these networks between patients with ICD and those with DDS using structural and resting-state functional magnetic resonance imaging. Methods: Patients with PD were recruited using the data from a previous cohort study and were divided into patients with ICB (ICB group) and those without ICB (non-ICB group) using the Japanese version of the Questionnaire for Impulsive Compulsive Disorders in Parkinson’s Disease (J-QUIP). From these two groups, we extracted 37 pairs matched for age, sex, disease duration, and levodopa equivalent daily dose of dopamine agonists. Patients with ICB were further classified as either having ICD or DDS based on the J-QUIP subscore. General linear models were used to compare the gray matter volume and functional connectivity (FC) of the NAcc, caudate, and putamen between the ICB and non-ICB groups and between patients with ICD and those with DDS. Results: We found no significant differences in gray matter volume between the ICB and non-ICB groups or between patients with ICD and those with DDS. Compared with the non-ICB group, the FC of the right NAcc in the ICB group was lower in the bilateral ventromedial prefrontal cortex and higher in the left middle occipital gyrus. Patients with DDS showed higher FC between the right putamen and left superior temporal gyrus and higher FC between the left caudate and bilateral middle occipital gyrus than patients with ICD. In contrast, patients with ICD exhibited higher FC between the left NAcc and the right posterior cingulate cortex than patients with DSS. Conclusions: The functionally altered network between the right NAcc and ventromedial prefrontal cortex was associated with the presence of ICB in PD, and the surrounding cortico-striatal networks may differentiate between the behavioral characteristics of patients with ICD and those with DDS.